p70S6K activation promotes the transdifferentiation of fibroblasts to myofibroblasts in pterygium tissue growth on the cornea
- 152 Downloads
To investigate the role of p70S6K in the transdifferentiation of fibroblasts to myofibroblasts in pterygium tissue growth on the cornea.
Quantitative real-time PCR and immunohistochemistry showed that p70S6K expression was higher in pterygium tissues than in normal conjunctival tissues. Higher p70S6K RNA expression levels were correlated with higher pterygium grades. Additionally, western blot analysis revealed that phosphorylated (activated) p70S6K (p-p70S6K) expression was significantly correlated with α-smooth muscle actin (α-SMA, a hallmark of transdifferentiation) expression in cultured human pterygium fibroblasts (HPFs). Furthermore, p70S6K knockdown and the specific mTOR inhibitor rapamycin decreased the expression levels of p-p70S6K and α-SMA in cultured fibroblasts from grade T3 pterygium.
p70S6K activation promotes the transdifferentiation of pterygium fibroblasts to myofibroblasts. Thus, targeting p70S6K may be a useful strategy in the management of pterygium.
KeywordsCornea Human pterygium fibroblasts p70S6K Pterygium tissue α-Smooth muscle actin Transdifferentiation
This work is supported by the National Natural Science Foundation of China (Grants Nos. 81370993; 81300736).
Supplementary Table 1—Sequences of PCR primers.
Supplementary Table 2—Differences in p-p70S6K protein expression between in pterygium tissues and conjunctival controls.
X-RZ: study conception and design, data collection and assembly, data analysis and interpretation, and manuscript writing; M-CZ: provision of study materials, acquisition of financial support, and data analysis and interpretation; H-TX: acquisition of financial support and data analysis and interpretation; NJ: data collection and assembly, data analysis and interpretation; L-TS: data collection and analysis.
Compliance with ethical standards
Conflict of interest
There are no financial conflicts of interest.
- Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRefPubMedGoogle Scholar